Drug intelligence / Profile preview

p300 siRNA

Development stage
Preclinical
Lead developer
Medical University of Innsbruck
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

p300 siRNA is a small interfering RNA designed to silence the expression of the E1A-binding protein p300 (EP300), a histone acetyltransferase and transcriptional coactivator. In prostate cancer, p300 is frequently upregulated and serves as a critical coactivator for the androgen receptor, promoting the transcription of genes that drive tumor progression even under low-androgen conditions. By targeting p300 mRNA for degradation, this siRNA approach induces caspase-dependent apoptosis through both intrinsic and extrinsic pathways and reduces the invasive potential of cancer cells by downregulating matrix metalloproteinase-9 (MMP-9). Research indicates that p300 and its paralog CBP have distinct roles, with p300 depletion specifically triggering cell death in both androgen-dependent and castration-resistant prostate cancer models, making it a potential therapeutic strategy for advanced malignancies.

Other names
EP300 siRNAEP-300 siRNAEP 300 siRNAp300-specific siRNAp-300-specific siRNAp 300-specific siRNAsiRNA targeting p300
02

Targets

EP300 (Histone acetyltransferase p300)

Beyond the preview

Go deeper on p300 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on p300 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call